I never took a position. I had some concerns about the trial hitting both end points and then from a BSTC standpoint I had some specific concerns on how long they would be entitled to EU royalties. Then after seeing Halozyme's program could be applicable in many of the same indications and potentially a much safer product I thought to stay out. Not that I saw the market putting a high value on Xiaflex in either company.
I didn't hear the call yet but saw some twitter posts. It seems there are some concerns about the results and what they have to show for approval.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.